Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study.
van Linschoten RCA, van der Woude CJ, Visser E, van Leeuwen N, Bodelier AGL, Fitzpatrick C, de Jonge V, Vermeulen H, Verweij KE, van der Wiel S, Nieboer D, Birnie E, van der Horst D, Hazelzet JA, van Noord D, West RL. van Linschoten RCA, et al. Among authors: bodelier agl. Inflamm Bowel Dis. 2024 Apr 26:izae095. doi: 10.1093/ibd/izae095. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38666643
Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West.
Arkenbosch JHC, Mak JWY, Ho JCL, Beelen EMJ, Erler NS, Hoentjen F, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, Ng SC, de Vries AC. Arkenbosch JHC, et al. Among authors: bodelier agl. Inflamm Bowel Dis. 2022 Jun 2;28(Suppl 2):S16-S24. doi: 10.1093/ibd/izab316. Inflamm Bowel Dis. 2022. PMID: 34969091
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: bodelier agl. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, Hoentjen F, van der Woude CJ; LADI study group. Jansen FM, et al. Among authors: bodelier agl. J Crohns Colitis. 2023 Nov 24;17(11):1771-1780. doi: 10.1093/ecco-jcc/jjad101. J Crohns Colitis. 2023. PMID: 37310877 Free PMC article. Clinical Trial.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group, the Dutch Initiative on Crohn, Colitis (ICC). van Linschoten RCA, et al. Among authors: bodelier agl. Dig Dis Sci. 2024 Apr 9. doi: 10.1007/s10620-024-08410-z. Online ahead of print. Dig Dis Sci. 2024. PMID: 38594435
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Römkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan ACITL, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens GRAM, van der Woude CJ, Duijvestein M, de Vries AC. Ten Bokkel Huinink S, et al. Among authors: bodelier agl. Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):983-992. doi: 10.1097/MEG.0000000000002403. Epub 2022 Aug 30. Eur J Gastroenterol Hepatol. 2022. PMID: 36062493
Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
Bak MTJ, Ten Bokkel Huinink S, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Hoentjen F, Stassen LPS, van der Meulen-de Jong AE, West RL, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC). Bak MTJ, et al. Among authors: bodelier agl. Am J Gastroenterol. 2024 Feb 1;119(2):306-312. doi: 10.14309/ajg.0000000000002509. Epub 2023 Nov 1. Am J Gastroenterol. 2024. PMID: 37737675 Free PMC article.
Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.
Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F. Biemans VBC, et al. Among authors: bodelier agl. Clin Pharmacol Ther. 2020 May;107(5):1189-1199. doi: 10.1002/cpt.1712. Epub 2019 Dec 11. Clin Pharmacol Ther. 2020. PMID: 31677154 Free PMC article.
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla ACTM, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmod N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ; Initiative on Crohns and Colitis (ICC). Kanis SL, et al. Gut. 2021 Jul;70(7):1266-1274. doi: 10.1136/gutjnl-2019-319129. Epub 2020 Oct 12. Gut. 2021. PMID: 33046558 Free PMC article.
43 results